Industry
Biotechnology
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Nabaparna Bhattacharya
June 14, 2024 | 2:06 pm
Portfolio Pulse from Avi Kapoor
June 14, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 11:24 am
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 6:50 am
Portfolio Pulse from Benzinga Insights
June 13, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 8:16 pm
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 8:16 pm
Portfolio Pulse from Benzinga Insights
May 14, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
May 13, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.